Custirsen
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Custirsen (also known as OGX-011 and CC-8490), usually supplied as its sodium salt, is an investigational drug that is under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving overall survival. Custirsen was developed through a collaboration between OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. agreed to develop and commercialize custirsen.
Custirsen (also known as OGX-011 and CC-8490), usually supplied as its sodium salt, is an investigational drug that is under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving overall survival. Custirsen was developed through a collaboration between OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. agreed to develop and commercialize custirsen. Clearance (CL) = 2.36 Central Volume of Distribution (V) = 6.08 Peripheral Volume of Distribution (V ) = 1.13 Volume of the Second Peripheral Compartment (V ) = 15.8
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329561987 under CC BY-SA 4.0; modifications have been made.